Status:
TERMINATED
Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis
Lead Sponsor:
Fox Chase Cancer Center
Collaborating Sponsors:
Ligand Pharmaceuticals
Conditions:
Parapsoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Parapsoriasis is a term that refers to a precursor stage of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides(MF). Complete responses (clearing) of early presentations of CTCL/MF have been shown to b...
Detailed Description
Parapsoriasis is a term that refers to a red, scaling (papulosquamous) eruption on the skin characterized by its distribution (trunk and proximal extremities), asymptomatic nature and chronic course. ...
Eligibility Criteria
Inclusion
- A clinical and histologic diagnosis of parapsoriasis (T0 CTCL)
- Age 18 years or older.
- Acceptable laboratory studies
- Must be free of serious concurrent illness.
- Women of child-bearing potential must have negative serum pregnancy test prior to the initiation of treatment.
Exclusion
- Topical or systemic therapies within four weeks of entry in the study.
- Participation in any other investigational drug study within thirty days of entry in this study.
- Oral retinoid therapy for any indication within three months of entry in the study.
- Participation in any other study using topical retinoid therapy.
- Pregnancy or active breast-feeding.
- Serious known concurrent medical illness or infection.
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2004
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00322296
Start Date
April 1 2001
End Date
August 1 2004
Last Update
April 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111